Search results for: 'Defense Data Analytics, Machine Learning, and Artificial Intelligence Growth Opportunities'

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Indu...

The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approach...

27 Aug 2020  |  Global  |  Market Research

Smart Labs as Key Drivers for the Digital Transformation of Diagnostic Laboratories, 2020

Robotic Automation, Internet of Things (IoT), and Artificial Intelligence (AI) Offering Growth Opportunities for Academic and Commercial Diagnostics Labs

Infographics

×

Key Issues Addressed

Diagnostic academic and commercial research labs suffer from cost pressures, given the ongoing Protecting Access to Medicare Act (PAMA) regulations and reproducibility issues, and are under productivity strain. The recent COVID-19 pandemic leading to increasing test volumes and renewed focus on research and development (R&D) to drive innovation wil...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

Pharmaceutical drug discovery and development processes suffer from declining success rates and a stagnant pipeline. Artificial Intelligence (AI) supported by Big Data could be a key element that can provide an effectual solution. There has been a rapid growth in the data generated within the life sciences and pharmaceutical industries. This stems ...

The global pharmaceutical industry is witnessing dynamic trends following the coronavirus pandemic and is adapting to new challenges and opportunities. This study analyzes the 2021 highlights in the global pharmaceutical industry and provides forecasts for the next year and beyond. It addresses the impact of innovative modalities, technologies, ...

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...